(October 19, 2017) BRCA1 and BRCA2 are among the most frequently mutated genes in ovarian cancer. Studies conducted in the past two decades have shown that BRCA1 and BRCA2 play … Continued
(October 13, 2017) The National Comprehensive Cancer Network currently recommends that early stage Ovarian Clear Cell Cancers be treated with adjuvant chemotherapy, or therapy given after the primary treatment as … Continued
(October 13, 2017) Every other year, the American Association for Cancer Research (AACR) brings together ovarian cancer researchers from around the world to share knowledge and encourage multi-disciplinary collaboration. At … Continued
(Oct. 11, 2017) Last week, the Trump Administration issued a regulation to immediately allow employers to deny insurance coverage for birth control on the basis of their own moral or … Continued
(September 15, 2017) Two studies just confirmed that, depending on one’s genetic background, the standard treatment for epithelial ovarian cancer is most likely the best option. The studies, conducted with … Continued
(September 8, 2017) Through its ongoing ‘AMORE, ITALIA, FOLONARI’ campaign, Folonari Wines has partnered this year with Ovarian Cancer Research Alliance. Joining forces with OCRFA gives Folonari a national platform … Continued
(September 5, 2017) Researchers at the University of Pennsylvania recently uncovered a link between one’s resistance to common types of chemotherapy and one’s tumor BRCA1/2 mutation status. More specifically, they … Continued
Every 23 minutes another woman is diagnosed with ovarian cancer. All of them have a story. This September, we’re inviting you to share your #OvarianStory. Help raise awareness of ovarian … Continued
(August 31, 2017) In answer to the persisting need for a cure to one of the deadliest diseases facing women today, Newk’s Eatery is calling on partners and patrons across … Continued
(August 22, 2017) The Journal of Clinical Oncology recently published a study about the unmet need of genetic testing in women with breast and ovarian cancer. Women who fit eligibility … Continued
(August 21, 2017) The US Food and Drug Administration (FDA) has granted full approval to olaparib tablets (Lynparza, AstraZeneca) for use as maintenance therapy for women with recurrent epithelial ovarian, … Continued
(August 9, 2017) The International Journal of Cancer recently published an article on preliminary findings for two factors that influence one’s risk of ovarian cancer, namely the age at which … Continued
Get email updates about research news, action alerts, and ways to join the fight.
